Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[DISCLOSURE] GNCO (065060) said on Sept. 7 that it will invest 3.62 billion won (US$3.31 million) in its subsidiary Sumagen by issuing 786,654 stocks to fund its clinical investigation for AIDS vaccine development.
The amount is equivalent to 2.59 percent of the company’s equity capital.
After the acquisition on Sept. 8, GNCO’s stake in the company will rise to 35.22 percent.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
The amount is equivalent to 2.59 percent of the company’s equity capital.
After the acquisition on Sept. 8, GNCO’s stake in the company will rise to 35.22 percent.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
